Correlation of 1-year vision outcomes with baseline factors in polypoidal choroidal vasculopathy patients after anti-VEGF treatment / 眼科新进展

ABSTRACT

Objective To analyze the correlation between baseline factors and the best corrected visual acuity (BCVA) after 3 monthly anti-vescular endothelial growth factor (VEGF) therapy in naive polypoidal choroidal vasculopathy (PCV).Methods This was a retrospective cohort study in 44 naive PCV patients (44 eyes) treated in our hospital between July 2015 and December 2016,and BCVA,optical coherence tomography (OCT) and fundus fluorescein angiography (FFA) + indocyanine green angiography (ICGA) examinations were performed at first.All patients were treated with monthly antiVEGF (including ranibizumab and conbercept) injections for 3 consecutive months,followed by the needed retreatment,and BCVA at the 12th month during follow-up after the first anti-VEGF treatment was recorded,following the comparison with baseline BCVA,and then the patients were divided into improved and unimproved groups according to BCVA changes.Finally,univariate and logistic regression analysis were used to analyze the correlation between the baseline factors and BCVA.Results The univariate analysis showed that the improved group had shorter onset time,smaller greatest linear dimension (P =0.045 and 0.037,respectively).Logistic regression showed the difference in choroidal vascular hyperpermeability and greatest linear dimension was statistically significant,suggesting that they were the independent predictors of visual outcome (regression coefficient =0.963 and 0.001,P =0.010 and 0.012,odds ratios =0.083 and 1.002,95％ confidence interval =0.013-0.549 and 1.001-1.004,respectively).Conclusion Choroidal vascular hyperpermeability may be a predictor for poor visual acuity prognosis in PCV patients after anti-VEGF,and greatest linear dimension and the time of onset are also related to postoperative visual acuity in PCV patients after anti-VEGF.